Get started
Author

Roshni Deepa Kalachand

Observed names: Kalachand, Roshni, Kalachand, Roshni D., R. Kalachand, Roshni Andrew Kalachand, Roshni D Kalachand, Roshni D. Kalachand, Roshni Deepa Deepa kalachand, Roshni Kalachand
Observed institutions: University College Dublin, Royal College of Surgeons in Ireland, University of Toronto, Beaumont Hospital, University Hospital Limerick, Tallaght University Hospital, St. Vincent's University Hospital, St. James's Hospital, Dublin City University, KU Leuven
ORCID: 0000-0003-3060-7877
Observed ORCID: 0000-0003-3060-7877
OpenAlex ID: A5030856084
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
2021 · I. Vergote, A. González-Martín, et al. · Annals of Oncology · 161
PDF
BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
2020 · Roshni D Kalachand, Britta Stordal, et al. · JNCI Journal of the National Cancer Institute · 68
PDF
Bortezomib‐induced reversible posterior leucoencephalopathy syndrome
2008 · Kevin Kelly, Roshni Kalachand, et al. · British Journal of Haematology · 25
Molecular Targeted Therapy in Ovarian Cancer
2011 · Roshni Kalachand, Bryan T. Hennessy, et al. · Drugs · 19
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
2020 · Sinead Toomey, Aoife Carr, et al. · Journal of Translational Medicine · 18
PDF
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
2022 · Mattia Cremona, Cassandra J. Vandenberg, et al. · British Journal of Cancer · 17
PDF
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2016 · Sinead Toomey, Alex J. Eustace, et al. · JNCI Journal of the National Cancer Institute · 15
PDF
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery
2014 · A. M. Mongan, R. Kalachand, et al. · Irish Journal of Medical Science (1971 -) · 12
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
2022 · Aashna Patel, Roshni Kalachand, et al. · Cochrane Database of Systematic Reviews · 11
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
2020 · Roshni D. Kalachand, Ciaran O’Riain, et al. · Obstetrics & Gynecology Science · 7
PDF
Adalimumab as therapy for fistulizing orofacial Crohnʼs disease
2009 · Glen Doherty, Roshni Kalachand, et al. · Inflammatory Bowel Diseases · 4
Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing
2018 · Christina Grimm, Axel Fischer, et al. · Journal of Molecular Diagnostics · 3
PDF
Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.
2015 · Roshni Deepa Kalachand, Ilary Ruscito, et al. · Journal of Clinical Oncology · 3
Perioperative epirubicin, oxaliplatin, and capectabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma.
2013 · Roshni Deepa Kalachand, Anne-Marie Mongan, et al. · Journal of Clinical Oncology · 3
Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)
2021 · Ruba Hamed, Sam Marks, et al. · Molecular and Clinical Oncology · 2
PDF
152P Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland
2021 · R.A. Mclaughlin, D. O'Reilly, et al. · Annals of Oncology · 2
Molecular Diagnostics in Cancer
2017 · Roshni D. Kalachand, Bryan T. Hennessy, et al. · Holland‐Frei Cancer Medicine · 2
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
2018 · Britta K Stordal, Roshni Kalachand, et al. · Cochrane Database of Systematic Reviews · 1
446 Docetaxel, Carboplatin and Trastuzumab (TCH) as Neoadjuvant (neoadj) Therapy in Patients (pts) with HER2-positive (HER2+) Operable Breast Cancer (BrCa)
2012 · M. Zuradelli, G. Gullo, et al. · European Journal of Cancer · 1
Prevalence of BRCA1/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program
2026 · Ciara S. McNevin, Kate Murphy, et al. · European Journal of Human Genetics
AB228. SOH26AB_0388. Investigation of time to adjuvant chemotherapy initiation following breast cancer surgery—a key performance indicator audit at University Hospital Limerick
2026 · Chrisen Ramkaran, Clara Forrest, et al. · Mesentery and Peritoneum
AB042. SOH26AB_0125. Incidence, contributing factors, and reversal of arm lymphoedema following a lymphoedema early detection service for breast cancer patients
2026 · Sinead Cobbe, Kathy Nugent, et al. · Mesentery and Peritoneum
Prevalence Of BRCA1/2 In An Ovarian Cancer Cohort: Outcomes From A Nationwide Testing Program
2025 · Ciara Mcnevin, Kate Murphy, et al. · International Journal of Gynecological Cancer
EV069/#1182 Radical chemoradiotherapy for cervical cancer: introduction of GCIG interlace into an Irish tertiary cancer centre
2024 · Dana Madigan, Emma Pounder, et al. · International Journal of Gynecological Cancer
Molecular Diagnostics in Cancer
2022 · Zachary L. Coyne, Roshni D. Kalachand, et al. · Holland‐Frei Cancer Medicine
Works count: 34
Citation count: 374
H-index: 9
I10-index: 9
Year
Topic
Type